Research Article | Open Access
Toxic Damage Increases Angiogenesis and Metastasis in Fibrotic Livers via PECAM-1
Excessive ethanol consumption is one of the main causes of liver fibrosis. However, direct effects of ethanol exposure on endothelial cells and their contribution to fibrogenesis and metastasis were not investigated. Therefore we analysed whether ethanol directly affects endothelial cells and if this plays a role during fibrogenesis and metastasis in the liver. Murine and human endothelial cells were exposed to ethanol for up to 72 hours. In vitro, effects on VEGF, HIF-1alpha, PECAM-1, and endothelial cell functions were analysed. In vivo, effects of continuous liver damage on blood vessel formation and metastasis were analysed by PECAM-1 immunohistochemistry. Ethanol increased HIF-1alpha and VEGF levels in murine and human endothelial cells. This resulted in enhanced intracellular signal transduction, and PECAM-1 expression as well as tube formation and wound healing. In vivo, toxic liver damage increased angiogenesis during fibrogenesis. Metastasis was also enhanced in fibrotic livers and located to PECAM-1 positive blood vessels compared to nonfibrotic mice. In conclusion, ethanol had strong effects on endothelial cells, which—at least in part—led to a profibrotic and prometastatic environment mediated by PECAM-1. Blockade of increased PECAM-1 expression could be a promising tool to inhibit fibrogenesis and metastasis in the liver.
Fibrosis and cirrhosis, respectively, are currently the tenth most common cause of death in western countries . One of the main causes of liver fibrosis/cirrhosis besides chronic hepatitis infection or hemochromatosis is excessive alcohol consumption . This leads to repeated damage/wound healing of the liver. During this process, hepatic stellate cells (HSC) are activated and contribute to the altered liver parenchyma [3, 4]. Besides the effect on HSC, liver sinusoidal cells (LSEC) are also affected by fibrogenesis. However, effects on endothelial cells of larger vessels were barely investigated. In the nonfibrotic liver, larger vessels are only found as branches of the hepatic artery or portal vein, whereas during fibrogenesis, the liver structure is altered and portal areas and septae are formed, which could originate from endothelial cells activated by proangiogenic chemokines.
Angiogenesis is a well-established mechanism during fibrogenesis of the liver. Fibrosis is characterised by intrahepatic vascular remodelling, with capillarisation of sinusoids, fibrogenesis, and development of intrahepatic shunts [5, 6]. This leads to hypoxia in the inflamed liver, which results in the increased expression of the hypoxia inducible factor HIF-1alpha, which in turn transactivates VEGF (vascular endothelial growth factor) [7, 8]. VEGF is secreted and binds to its receptors on endothelial cells inducing—via intracellular signal transduction cascades—endothelial cell survival, migration, adhesion, and differentiation which leads to angiogenesis and blood vessel formation [9–12]. Recent studies suggest that pathological angiogenesis, as occurring in fibrogenesis, is a main contributor to disease progression [6, 13]. But not only fibrogenesis, but also tumour growth and metastasis are increased by fibrogenesis and angiogenesis, as was demonstrated in a previous study by our workgroup . It is well known that the altered extracellular matrix promotes tumour growth and metastasis in the liver (reviewed in ). However, effects on endothelial cells and related cell adhesion molecules like PECAM-1 were not investigated. This is of special interest since cell adhesion molecules are known to mediate the adhesion of tumour cells to the endothelium which is a crucial step in metastasis formation [16, 17].
Therefore, we investigated if alcohol uptake directly affects endothelial cells (not liver sinusoids) and the corresponding cell adhesion molecule PECAM-1 during fibrogenesis and if this plays a role in metastasis formation. These molecular insights could contribute to the development of new antiangiogenic treatment strategies.
2. Materials and Methods
2.1. Animals and Cell Lines
Eight-week old male C3H mice were supplied by Charles River (Sulzfeld, Germany) and kept in the local central animal facility of the University Hospital Bonn. The mice were housed under standard conditions and had free access to water and food. Animal procedures were performed in accordance with approved protocols and followed recommendations for proper care and use of laboratory animals.
The murine endothelial cell line SVEC4-10 (ATCC CRL-2181) was obtained from LGC Promochem (Wesel, Germany) and cultured in DMEM supplemented with 10% FBS, 200 mM glutamine. HUVE-cells (HUVEC, pooled) were obtained from PromoCell (Heidelberg, Germany) and cultured in EGM with supplements according to the manufacturer’s instructions.
Hepa129 cells (Hepatoma 129, obtained from NCI-Frederick Cancer Research and Development Centre (DCT Tumour Repository)) were maintained in RPMI1640 supplemented with 10% FBS, 200 mM glutamine.
2.2. Induction of Toxic Damage In Vitro/In Vivo and Tumour Cell Implantation
Murine SVEC4-10 and human HUVE cells were incubated with 100 mM ethanol for a time period of three days. Every day, a subgroup of the cells ( per group) was harvested and processed for further analysis.
In vivo, fibrosis was induced in female C3H mice according to a previous publication using TAA (200 mg/g bodyweight) and ethanol (10% in drinking water) . As a control, age matched nonfibrotic mice were used. Every four weeks a subgroup of nonfibrotic and fibrotic animals were sacrificed and livers were harvested for RNA isolation and immunohistochemistry.
16 weeks after starting fibrosis induction, orthotopic tumours were induced by injecting 105 Hepa129 cells in the left liver lobe as described in a previous publication . After tumour cell implantation, TAA and ethanol application was prolonged.
2.3. Cell Viability
The cells were seeded in 96-well plates (5 × 103 cells/well) and treated with ethanol for up to 72 hours ( = 4 per group). Untreated cells were used as controls. To analyse cell proliferation, every 24 hours a subgroup of the cells was incubated with the tetrazolium salt (MTT) and afterwards solubilized with DMSO. Optical density was determined using the GloMax Multi Reader (Promega, Mannheim) at 560 nm.
2.4. Analysis of Angiogenic Gene Expression In Vitro and In Vivo
SVEC4-10 or HUVE cells were seeded on 10 cm dishes. One day later, the cells were treated with 100 mM ethanol for 0, 24, 48, and 72 hours. Subsequently, protein or RNA was isolated.
Every four weeks a subgroup of fibrotic and nonfibrotic mice was sacrificed and livers were explanted for further investigation. Liver fragments (50 mm3) or cells were homogenised in PBS with protease inhibitors (Complete, Roche Diagnostics) or lysis buffer #11 according to previous publications [19, 20]. The whole protein content was determined and 100 μg protein for the VEGF-ELISA and 200 μg protein for the HIF-1alpha ELISA (both from R&D Systems, Wiesbaden, Germany) were used.
RNA from SVEC4-10 and HUVEC was isolated with the high pure RNA isolation Kit (Roche Diagnostics) and RNA from nonfibrotic and fibrotic livers was isolated with the high pure RNA tissue Kit (Roche Diagnostics). RNA was reverse transcribed (transcriptor first strand cDNA synthesis Kit, Roche Diagnostics) and a semiquantitative real time PCR for PECAM-1 (mouse left: 5′-agc cag tag cat cat ggt ca-3′, mouse right: 5′-agc agg aca ggt cca aca ac-3′, universal probe library number #25; human left: 5′-gca aca cag tcc aga tag tcg t-3′, human right: 5′-gac ctc aaa ctg ggc atc at-3′, universal probe library number #26) was done using LightCycler technique according to previous publication . Relative expression levels were determined using ALAS1 as housekeeping gene. Primers were obtained from Sigma-Aldrich (Munich, Germany) and probes from Roche Diagnostics.
To analyse the localisation of PECAM-1 during fibrosis development in vivo, immunohistochemistry for PECAM-1 was performed. Cryopreserved liver sections from fibrotic (tumour bearing) and nonfibrotic (tumour bearing) mice were immunostained with monoclonal rat anti-mouse CD31 (eBioscience). The sections were incubated with a corresponding secondary antibody. Detection was done using streptavidin and AEC substrate (Dako cytomation, Hamburg, Germany). Sections were counterstained with hematoxylin.
2.5. Analysis of Intracellular Signal Transduction
The cells were incubated with ethanol as described above. Effects on intracellular signal transduction were analysed using ELISA for phosphorylated AKT, ERK, and MAPK p38 (R&D Systems, Wiesbaden, Germany). Cell lysis was performed with lysis buffer #6 according to the manufacturer’s instructions. Protein content was determined with the DC protein assay according to the manufacturer’s instructions. 100 μg protein was subjected to the ELISA.
Effects on Stat3 were investigated in a cell based ELISA (R&D Systems). For this, 5 × 103 HUVEC or SVEC4-10 were seeded on a black 96-well cell culture plate. The assay was performed in accordance with the manufacturer’s protocol. Fluorescence of total and phosphorylated Stat3 was determined with the provided green and UV filter (GloMax Multi). Data was expressed as relative fluorescence units (RFU).
2.6. Analysis of Functional Effects on Endothelial Cells In Vitro
SVEC4-10 and HUVEC were incubated with ethanol as described above. 42 hours later, the cells were detached and 2.5 × 104 cells were seeded on 300 μL Matrigel (mixed with 100 ng/mL human or murine VEGF) in a 24-well plate. Incubation with ethanol was prolonged for another 6 hours. Tube formation was then determined using an inverted microscope by counting the whole circular tube-like structures per high power field ( hpf per group).
Endothelial cell migration was investigated by an in vitro wound healing assay. For this, 105 SVEC4-10 or HUVEC were seeded in 12-well plates. 24 hours later, the cells were treated with ethanol and a scratch “wound” was applied to the cells. Ethanol damage was prolonged during the whole experiment. Every 24 hours, the cultures were analysed under a light microscope for migration of the cells in the unoccupied area. The widths of the gaps were measured at three reading points per hpf ( hpf/group) using Axiovision imaging software (Carl Zeiss, Jena, Germany).
2.7. Statistical Analysis
Data has been expressed as mean ± SEM. Diversity of different experimental groups was analysed for statistical significance by a nonparametric, two-tailed test (Mann-Whitney) for unpaired samples. Significance was calculated by the log-rank test. has been considered to be significant.
3.1. Cell Viability Is Slightly Increased after Treatment with Ethanol
First, we investigated if ethanol affects overall cell viability in endothelial cells. In SVEC4-10, three days of 1000 mM ethanol damage reduced cell viability by 23% compared to untreated cells (Figure 1(a)). In HUVE cells, one day after starting ethanol treatment, 250 mM ethanol decreased cell viability by 14% compared to the control. Incubation of HUVE cells with 1000 mM ethanol for three days reduced cell viability by 58% compared to the corresponding control (Figure 1(b)). Since 100 mM ethanol was the maximum tolerable concentration, all further experiments were conducted with it.
3.2. Toxic Damage Increases the Expression of Proangiogenic Factors in Endothelial Cells In Vitro
Ethanol is known to induce hypoxia in fibrotic livers . We therefore tested whether ethanol directly increased HIF-1alpha and subsequently VEGF in endothelial cells.
In SVEC4-10, ethanol exposure increased HIF-1alpha by 15% compared to untreated cells. Another 24 hours later, HIF-1alpha was increased by 32% compared to the control. Three days of ethanol exposure increased HIF-1alpha by 51% compared to untreated cells (Figure 2(a)). In analogy to the increase in HIF-1alpha expression, ethanol also increased VEGF expression: one day of ethanol exposure elevated VEGF by 18% compared to the control. 48 hours of ethanol treatment increased VEGF 1.9-fold compared to untreated cells. After 72 hours of ethanol, VEGF expression was enhanced 2.3-fold compared to untreated cells (Figure 2(b)).
This was also observed in HUVE cells: 24 hours of ethanol treatment increased HIF-1alpha expression by 9% compared to the control. Another 24 hours later, HIF-1alpha was elevated by 21% compared to untreated cells. Three days of ethanol damage increased HIF-1alpha by 31% compared to undamaged cells (Figure 2(c)). This went in line with VEGF protein levels. One day following ethanol treatment, VEGF was enhanced by 27% compared to untreated cells. Two days of ethanol damage increased VEGF by 41% compared to the control. Three days of ethanol treatment elevated VEGF by 67% compared to untreated cells (Figure 2(d)).
3.3. Ethanol Increases the Expression of the Endothelial Cell Adhesion Molecule PECAM-1
After showing that ethanol increased proangiogenic factors like HIF-1a and VEGF, we investigated whether treatment with ethanol also affected the endothelial cell adhesion molecule PECAM-1. PECAM-1 plays a prominent role in VEGF induced endothelial cell migration and tube formation. In SVEC4-10, 24 hours after initiating ethanol treatment, PECAM RNA levels were increased 4.5-fold () compared to the control (, , ). Another 24 hours later, ethanol increased PECAM expression 8-fold () compared to the undamaged control (, , ). On day three of ethanol treatment, PECAM also increased 6.9-fold () compared to untreated cells (, , ).
In HUVEC, similar effects were observed: 24 hours of ethanol damage increased PECAM-RNA levels 3.9-fold () compared to untreated cells (, , ). Two days of ethanol exposure increased PECAM expression 6.0-fold compared to the control ( versus , = 4, ). Another 24 hours of ethanol treatment increased PECAM 5.7-fold compared to untreated cells ( versus , , ).
3.4. Increased Angiogenic Gene Expression Results in Increased Intracellular Signal Transduction in Endothelial Cells
After detecting an ethanol induced increase in PECAM-1 gene and protein expression, it was intriguing to investigate if this leads to enhanced intracellular signal transduction. To analyse this, we performed ELISA for phosphorylated ERK1/2, P38 MAPK, and JNK.
In SVEC4-10, 24 hours of ethanol increased phosphorylation of ERK1/2 by 27% compared to the controls. Another 24 hours of ethanol exposure increased pERK1/2 by 32% compared to untreated cells. 72 hours of ethanol damage further increased phosphorylation of ERK1/2 (by 35%) compared to undamaged cells. Analysis of phosphorylated P38 MAPK showed after 24 hours a 4.3-fold increase in ethanol treated cells compared to untreated controls. Two days of ethanol exposure enhanced pP38 MAPK 6-fold compared to untreated cells. 72 hours after the addition of ethanol pP38 MAPK was further increased (6.5-fold) compared to the control. Phosphorylation of JNK was also increased (by 25%) after 24 hours of ethanol exposure compared to the control. 48 hours after starting ethanol damage, pJNK was elevated by 37% compared to undamaged cells. Another 24 hours later, JNK phosphorylation was slightly reduced compared to day two but still increased (by 35%) compared to untreated control cells (Figure 3(a)).
The effects of ethanol on intracellular signal transduction were similar in HUVE cells: phosphorylation of ERK1/2 was also enhanced in HUVE cells (by 41%) after 24 hours of ethanol exposure compared to the control. Two days after initiation of ethanol damage, pERK1/2 was increased by 39% compared to undamaged cells. Another day later, pERK1/2 was elevated by 56% in ethanol treated cells compared to untreated HUVEC. Corresponding to SVEC4-10, phosphorylation of P38 MAPK also strongly increased following ethanol exposure. 24 hours of ethanol damage increased pP38 MAPK 1.8-fold compared to undamaged cells. Another 24 hours later pP38 MAPK was enhanced 2-fold in ethanol treated cells compared to the control. Three days of ethanol treatment further increased phosphorylation of P38 MAPK (2.6-fold) compared to control cells. Phosphorylation of JNK was also increased (by 15%) after 24 hours of ethanol exposure compared to the control. 48 hours after starting ethanol damage, pJNK was elevated by 26% compared to undamaged cells. Another 24 hours later, JNK phosphorylation was further enhanced (by 32%) compared to day two and control cells (Figure 3(b)).
PECAM-1 is thought to induce Stat3 phosphorylation . Here, phosphorylation of Stat3 as determined by a fluorescent cell based ELISA showed that one day of ethanol exposure increased pStat3 5-fold compared to untreated cells. Two and three days of ethanol damage increased phosphorylated Stat3 in SVEC4-10 10-fold compared to the untreated controls (Figure 4(a)). In HUVEC, one day of ethanol treatment increased pStat3 by 13% compared to the control. Two days of ethanol damage increased phosphorylation of Stat3 by 30% compared to untreated cells. Another day later ethanol enhanced pStat3 1.6-fold compared to the control (Figure 4(b)).
3.5. Enhanced Intracellular Signal Transduction Results in Increased Tube Formation and Migration In Vitro
The phosphorylation of, for example, ERK1/2 and P38 MAPK leads to increased migration and tube formation in endothelial cells. We therefore tested whether the enhanced intracellular signal transduction shown here resulted also in increased tube formation and migration.
After 24 hours of ethanol exposure, tube formation was increased 1.6-fold (39.5 tubes/well ± 9.7) in SVEC4-10 compared to untreated cells (24.7 tubes/well ± 6.8, , ). Another 24 hours later, tube formation was increased 2.7-fold (75.5 tubes/well ± 9.7) compared to the control (28.3 tubes/well ± 10.3, , ). Three days of ethanol exposure also increased tube formation (2.1-fold, 55.7 tubes/well ± 8.2) compared to control cells (26.5 tubes/well ± 4.9, , , Figure 5(a)).
Similar results were obtained for HUVEC: 24 hours of ethanol treatment increased tube formation 1.5-fold (31.0 tubes/well ± 3.9) compared to the control (20.7 tubes/well ± 3.1, , ). Ethanol also increased tube formation 1.8-fold (30.3 tubes/well ± 4.9) compared to untreated cells (16.8 tubes/well ± 2.2, , ) after 48 hours of ethanol exposure. Another 24 hours later, ethanol enhanced tube formation 1.9-fold (35.0 tubes/well ± 4.7) compared to the control (18.4 tubes/well ± 3.6, , , Figure 5(b)).
Wound healing was also increased in both cell lines. In SVEC4-10, ethanol increased the closure of the “wound” by 89% (21.86 μm ± 15.01 μm) after 24 hours compared to the control (191.99 μm ± 38.41 μm, , ). After two days of ethanol damage, no measurable gap in ethanol treated and control cells was detected (Figure 6(a)). In HUVE cells, the wound closure was enhanced by 31% (333.6 μm ± 9.9 μm) after 24 hours of ethanol damage compared to the untreated control (483.3 μm ± 24.7 μm, , ). Two days after initiating ethanol damage, the gap was further reduced (by 46%, 194.1 μm ± 44.4 μm) compared to the control (357.4 μm ± 25.3 μm, , ). After 72 hours of ethanol damage, the gap was no longer detectable in ethanol treated cells, whereas, in the controls, a small gap (117.5 μm ± 32.2 μm, , ) was still visible (Figure 6(b)).
3.6. Endothelial Cells Establish New Blood Vessels during Fibrogenesis
Ethanol exposure plays a prominent role in the development of fibrosis in western countries. Therefore, we tested whether development of fibrosis in a mouse model showed also altered PECAM expression. This could contribute—among other things—to a protumoural environment.
Development of fibrosis was confirmed by van Gieson staining (data not shown). After four weeks of toxic liver damage, PECAM-1 gene expression increased 1.8-fold compared to the control. Another eight and twelve weeks after initiation of liver damage, PECAM-1 was elevated 1.4-fold and 1.6-fold compared to the corresponding nonfibrotic control. Sixteen weeks of liver damage increased PECAM-1 2-fold compared to untreated animals (Table 1). Detection of PECAM-1 by immunohistochemistry revealed that the cell adhesion molecule was mainly located in the developing portal tracts during fibrogenesis with increasing staining intensity (Figure 7(a)).
, n.s.: not significant. |
Ten days after tumour cell implantation, fibrotic livers showed larger tumours and more metastases compared to nonfibrotic livers, which mainly possessed one singular tumour (Figure 7(b)). Microscopic analysis showed that, in fibrotic livers, metastases were mainly located adjacent to blood vessels, whereas, in nonfibrotic animals, metastasis formation was not detected (Figure 7(c)).
Liver cirrhosis is currently the tenth most common cause of death in western countries with alcohol being one of the main inducers of fibrosis/cirrhosis [1, 2]. On the molecular level, the process of repeated damage and repair activates HSC, leading to defenestration of liver sinusoids and excessive alteration of the extracellular matrix [5, 24]. However, direct effects of ethanol on larger blood vessels and the corresponding endothelial cells were barely investigated although increased blood vessel formation increases metastatic risk [25, 26].
Therefore, we analysed whether ethanol damage directly affected endothelial cells and angiogenesis in vitro and in vivo. For this, effects of ethanol on HIF-1alpha, VEGF, intracellular signal transduction, and proangiogenic properties of murine and human endothelial cells were analysed. Angiogenesis in vivo was investigated in a murine fibrosis model by staining endothelial vessels for PECAM-1 (CD31). To test if increased angiogenesis also leads to increased metastasis, we applied an orthotopic tumour model.
Toxic liver damage elevated HIF-1alpha and VEGF protein levels, which not only resulted in enhanced intracellular signal transduction, but also led to increased proangiogenic effects like wound healing and tube formation. In vivo, staining intensity of PECAM-1 increased during fibrogenesis and was localised at the evolving portal areas. In fibrogenic animals metastasis was increased and localised adjacent to blood vessels. Further analysis showed that PECAM-1 expression was not only increased in the portal areas, but also in endothelial cells themselves after ethanol damage in vitro.
Ethanol was used to simulate fibrosis in vitro. Since ethanol is toxic, we first investigated if ethanol affected cell viability. Administration of 100 mM ethanol over a time period of three days did not considerably affect cell viability. We chose this moderate alcohol concentration to analyse “long term” effects in vitro. Despite this moderate alcohol concentration, HIF-alpha and particularly VEGF were strongly increased after ethanol treatment. That HIF-1a is increased following ethanol damage was shown in liver sinusoidal endothelial cells derived from ethanol fed rats and in human dermal microvascular cells . Some studies propose—in analogy to, for example, tumour cells—an autocrine loop in endothelial cells due to hypoxic stress . Loss of HIF-1alpha inhibits VEGF expression and endothelial cell functions . So, an increase in HIF-1alpha, as shown in the presented study, could display reciprocal effects in the analysed endothelial cells.
In line with this, increased VEGF also increased intracellular signal transduction. Mainly, molecules leading to increased endothelial cell functions, like migration, adhesion, and tube formation were phosphorylated. We also analysed phosphorylation of Stat3, since pStat3 is known to activate VEGF expression . Stat3 phosphorylation was increased as well, going in line with the increased VEGF levels. In another study, targeting Stat3 by using a small molecule inhibitor blocked not only VEGF, but HIF-1alpha as well , being another hint for autocrine mechanisms in the analysed endothelial cells. The enhanced intracellular signal transduction resulted in increased endothelial cell migration and adhesion as was determined by a wound healing assay and a matrigel assay. This data confirms results from a previous study by Morrow et al.: after 24 hours of incubation with 25 mM ethanol, tube formation and wound healing was increased in HUVE cells compared to untreated cells . However, in this study effects were analysed for 24 hours.
After demonstrating that toxic damage using ethanol had proangiogenic effects in vitro, we transferred the results in an in vivo model. Fibrosis in mice was induced with intraperitoneal injections of TAA and additional ethanol feeding. Previous studies by our workgroup showed that fibrosis develops within 10 to 15 weeks . In these studies, we focused on fibrotic gene and protein expression, like the intercellular adhesion molecule ICAM and matrix metalloproteases [14, 18]. Here, we focused on angiogenesis: immunohistochemistry showed increasing staining intensity of PECAM-1 in the portal tracts during fibrogenesis. PECAM-1 is mainly expressed on endothelial cells where it mediates cell-cell contacts, vascular permeability, coagulation, and transmigration of leukocytes . Furthermore, it plays a major role in angiogenesis and inflammation [33, 34]. PECAM-1 was not detected in the septae or sinusoids in our study. Couvelard et al. also showed that LSEC do not express PECAM-1 independent of toxic damage . Since in the control group no PECAM-1 was detected and bearing in mind that ethanol did not affect endothelial cell proliferation or apoptosis, we hypothesize that these effects were due to increased migration of endothelial cells as was shown in vitro. This led us to the assumption that PECAM-1 could also mediate effects in fibrogenesis. That PECAM-1 plays a role during fibrogenesis was already demonstrated .
Increased angiogenesis is also linked with an increased risk of metastasis [25, 26]. So, we tested whether increased angiogenesis as shown in our study here also led to increased metastasis. In analogy to a previous study by our workgroup , tumour growth and metastasis were increased compared to tumour bearing nonfibrotic animals. In the previous study, focus was laid on proangiogenic factors, like VEGF and its receptors, whereas effects on the cell adhesion molecule PECAM-1 as a mediator of angiogenesis and metastasis were not investigated. Here, we could show that tumour cells were mainly located adjacent to PECAM-1 positive blood vessels in fibrotic livers, further highlighting the role of PECAM-1.
The increase of PECAM-1 during fibrogenesis could be due to an either increased number of endothelial cells or increased PECAM-1 gene and protein expression on endothelial cells. Therefore, we also investigated if ethanol directly affected PECAM-1 expression on endothelial cells. Surprisingly, PECAM-1 was increased after treatment with ethanol in both cell lines. In a previous study, increased VEGF induces TNF-alpha which in turn resulted in increased PECAM-expression. Furthermore, it is postulated that Stat3 is activated by PECAM-1, providing an alternative mechanism: Ilan and coworkers showed that PECAM-1 mediates Stat family signal transduction . This could contribute to the effects of ethanol observed in our study. PECAM-1 could also—at least in part—mediate endothelial cell migration and capillary morphogenesis/tube formation. This was already demonstrated for mouse kidney endothelial cells. These cells derived from PECAM−/− mice showed reduced abilities to form tubes and migrate compared to PECAM+/+ mice .
After showing that PECAM-1 plays a role during fibrogenesis, the therapeutic potential of PECAM-1 has now to be investigated. As was shown for VEGF, VEGF inhibition via the therapeutic antibody bevacizumab had inhibitory effects on fibrogenesis , as well as the application of VEGF expressing plasmid vector . As the role of VEGF is controversial regarding the treatment of fibrosis, we hypothesize that it is the same with PECAM-1. During fibrogenesis, defenestration occurs with increasing resistance to blood flow [6, 39]. Therefore, blockade of PECAM-1 and decreased blood vessel formation could lead to increased portal hypertension. On the other hand, blockade of PECAM-1 could be beneficial regarding tumour growth and metastasis in the fibrotic liver. Further investigations have to clarify the therapeutic role of PECAM-1 in the treatment of fibrosis and correlating tumour growth.
In conclusion, ethanol activates endothelial cells resulting in increased angiogenesis. This leads to a profibrotic and prometastatic environment, which is—at least in part—mediated by increased PECAM-1 expression on endothelial cells. This in turn results in increased metastasis formation in the fibrotic liver. Blockade of PECAM-1 by, for example, RNA interference could be a promising tool to inhibit fibrogenesis and metastasis in the liver.
Conflict of Interests
The authors declare that there is no conflict of interests regarding the publication of this paper.
Esther Raskopf and Maria Angeles Gonzalez Carmona contributed equally to this work.
This work was supported by a Deutsche Krebshilfe grant to Esther Raskopf and Volker Schmitz.
- S. F. Stewart and C. P. Day, “The management of alcoholic liver disease,” Journal of Hepatology, vol. 38, no. 1, supplement, pp. S2–S13, 2003.
- H. Tilg and C. P. Day, “Management strategies in alcoholic liver disease,” Nature Clinical Practice Gastroenterology and Hepatology, vol. 4, no. 1, pp. 24–34, 2007.
- D. Li and S. L. Friedman, “Liver fibrogenesis and the role of hepatic stellate cells: new insights and prospects for therapy,” Journal of Gastroenterology and Hepatology, vol. 14, no. 7, pp. 618–633, 1999.
- R. Safadi and S. L. Friedman, “Hepatic fibrosis—role of hepatic stellate cell activation,” Medscape General Medicine, vol. 4, no. 3, article 27, 2002.
- R. Bataller and D. A. Brenner, “Liver fibrosis,” Journal of Clinical Investigation, vol. 115, no. 2, pp. 209–218, 2005.
- L. Valfrè di Bonzo, E. Novo, S. Cannito et al., “Angiogenesis and liver fibrogenesis,” Histology and Histopathology, vol. 24, no. 10, pp. 1323–1341, 2009.
- J. A. Forsythe, B.-H. Jiang, N. V. Iyer et al., “Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1,” Molecular and Cellular Biology, vol. 16, no. 9, pp. 4604–4613, 1996.
- P. Yu and T. Kodadek, “Dynamics of the hypoxia-inducible factor-1-vascular endothelial growth factor promoter complex,” Journal of Biological Chemistry, vol. 282, no. 48, pp. 35035–35045, 2007.
- T. Takahashi, H. Ueno, and M. Shibuya, “VEGF activates protein kinase C-dependent, but Ras-independent Raf-MEK-MAP kinase pathway for DNA synthesis in primary endothelial cells,” Oncogene, vol. 18, no. 13, pp. 2221–2230, 1999.
- M. Shibuya, “Structure and function of VEGF/VEGF-receptor system involved in angiogenesis,” Cell Structure and Function, vol. 26, no. 1, pp. 25–35, 2001.
- M. Shibuya and L. Claesson-Welsh, “Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis,” Experimental Cell Research, vol. 312, no. 5, pp. 549–560, 2006.
- I. Zachary, “VEGF signalling: integration and multi-tasking in endothelial cell biology,” Biochemical Society Transactions, vol. 31, pp. 1171–1177, 2003.
- J. Medina, A. G. Arroyo, F. Sánchez-Madrid, and R. Moreno-Otero, “Angiogenesis in chronic inflammatory liver disease,” Hepatology, vol. 39, no. 5, pp. 1185–1195, 2004.
- M. Kornek, E. Raskopf, R. Tolba et al., “Accelerated orthotopic hepatocellular carcinomas growth is linked to increased expression of pro-angiogenic and prometastatic factors in murine liver fibrosis,” Liver International, vol. 28, no. 4, pp. 509–518, 2008.
- D. Y. Zhang and S. L. Friedman, “Fibrosis-dependent mechanisms of hepatocarcinogenesis,” Hepatology, vol. 56, no. 2, pp. 769–775, 2012.
- L. Weiss, Principles of Metastasis, Academic Press, Orlando, Fla, USA, 1985.
- L. Weiss, F. W. Orr, and K. V. Hohn, “Interactions of cancer cells with the microvasculature during metastasis,” FASEB Journal, vol. 2, no. 1, pp. 12–21, 1988.
- M. Kornek, E. Raskopf, I. Guetgemann et al., “Combination of systemic thioacetamide (TAA) injections and ethanol feeding accelerates hepatic fibrosis in C3H/He mice and is associated with intrahepatic up regulation of MMP-2, VEGF and ICAM-1,” Journal of Hepatology, vol. 45, no. 3, pp. 370–376, 2006.
- E. Raskopf, A. Vogt, T. Sauerbruch, and V. Schmitz, “siRNA targeting VEGF inhibits hepatocellular carcinoma growth and tumor angiogenesis in vivo,” Journal of Hepatology, vol. 49, no. 6, pp. 977–984, 2008.
- E. Raskopf, A. Vogt, G. Decker et al., “Combination of hypoxia and RNA-interference targeting VEGF induces apoptosis in hepatoma cells via autocrine mechanisms,” Current Pharmaceutical Biotechnology, vol. 13, no. 11, pp. 2290–2298, 2012.
- M. Kornek, V. Lukacs-Kornek, A. Limmer et al., “1,2-Dioleoyl-3-trimethylammonium-propane (DOTAP)- formulated, immune-stimulatory vascular endothelial growth factor a small interfering RNA (siRNA) increases antitumoral efficacy in murine orthotopic hepatocellular carcinoma with liver fibrosis,” Molecular Medicine, vol. 14, no. 7-8, pp. 365–373, 2008.
- S. K. Das, S. Mukherjee, and D. M. Vasudevan, “Effects of long term ethanol consumption mediated oxidative stress on neovessel generation in liver,” Toxicology Mechanisms and Methods, vol. 22, no. 5, pp. 375–382, 2012.
- N. Ilan, L. Cheung, S. Miller, A. Mohsenin, A. Tucker, and J. A. Madri, “PECAM-1 is a modulator of STAT family member phosphorylation and localization: lessons from a transgenic mouse,” Developmental Biology, vol. 232, no. 1, pp. 219–232, 2001.
- K. Wallace, A. D. Burt, and M. C. Wright, “Liver fibrosis,” Biochemical Journal, vol. 411, no. 1, pp. 1–18, 2008.
- Y. F. Jiang, Z. H. Yang, and J. Q. Hu, “Recurrence or metastasis of HCC: predictors, early detection and experimental antiangiogenic therapy,” World Journal of Gastroenterology, vol. 6, no. 1, pp. 61–65, 2000.
- J. Folkman, “Role of angiogenesis in tumor growth and metastasis,” Seminars in Oncology, vol. 29, no. 6, pp. 15–18, 2002.
- S. Yeligar, H. Tsukamoto, and V. K. Kalra, “Ethanol-induced expression of ET-1 and ET-BR in liver sinusoidal endothelial cells and human endothelial cells involves hypoxia-inducible factor-1α and microRNA-199,” Journal of Immunology, vol. 183, no. 8, pp. 5232–5243, 2009.
- I. Nilsson, M. Shibuya, and S. Wennström, “Differential activation of vascular genes by hypoxia in primary endothelial cells,” Experimental Cell Research, vol. 299, no. 2, pp. 476–485, 2004.
- N. Tang, L. Wang, J. Esko et al., “Loss of HIF-1α in endothelial cells disrupts a hypoxia-driven VEGF autocrine loop necessary for tumorigenesis,” Cancer Cell, vol. 6, no. 5, pp. 485–495, 2004.
- Q. Xu, J. Briggs, S. Park et al., “Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways,” Oncogene, vol. 24, no. 36, pp. 5552–5560, 2005.
- D. Morrow, J. P. Cullen, P. A. Cahill, and E. M. Redmond, “Ethanol stimulates endothelial cell angiogenic activity via a Notch- and angiopoietin-1-dependent pathway,” Cardiovascular Research, vol. 79, no. 2, pp. 313–321, 2008.
- A. Woodfin, M.-B. Voisin, and S. Nourshargh, “PECAM-1: a multi-functional molecule in inflammation and vascular biology,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 27, no. 12, pp. 2514–2523, 2007.
- N. Ilan and J. A. Madri, “PECAM-1: old friend, new partners,” Current Opinion in Cell Biology, vol. 15, no. 5, pp. 515–524, 2003.
- P. J. Newman and D. K. Newman, “Signal transduction pathways mediated by PECAM-1: new roles for an old molecule in platelet and vascular cell biology,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 23, no. 6, pp. 953–964, 2003.
- A. Couvelard, J.-Y. Scoazec, and G. Feldmann, “Expression of cell-cell and cell-matrix adhesion proteins by sinusoidal endothelial cells in the normal and cirrhotic human liver,” American Journal of Pathology, vol. 143, no. 3, pp. 738–752, 1993.
- S. Kondo, E. A. Scheef, N. Sheibani, and C. M. Sorenson, “PECAM-1 isoform-specific regulation of kidney endothelial cell migration and capillary morphogenesis,” American Journal of Physiology, vol. 292, no. 6, pp. C2070–C2083, 2007.
- Y. Huang, H. Feng, T. Kan et al., “Bevacizumab attenuates hepatic fibrosis in rats by inhibiting activation of hepatic stellate cells,” PLoS ONE, vol. 8, no. 8, Article ID e73492, 2013.
- H. Xu, B.-M. Shi, X.-F. Lu et al., “Vascular endothelial growth factor attenuates hepatic sinusoidal capillarization in thioacetamide-induced cirrhotic rats,” World Journal of Gastroenterology, vol. 14, no. 15, pp. 2349–2357, 2008.
- S. L. June, D. Semela, J. Iredale, and V. H. Shah, “Sinusoidal remodeling and angiogenesis: a new function for the liver-specific pericyte?” Hepatology, vol. 45, no. 3, pp. 817–825, 2007.
Copyright © 2014 Esther Raskopf et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.